<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Human T-lymphotropic virus 1</segment>
<segment id="3" parent="2" relname="restatement">( HTLV-1 )</segment>
<segment id="4" parent="1003" relname="same_unit">is a Deltaretrovirus ,</segment>
<segment id="5" parent="1003" relname="elaboration">endemic in Japan , Caribbean , South America , Sub-Saharan Africa , and Melanesia .</segment>
<segment id="6" parent="1005" relname="joint">HTLV-1 is associated with several different types of diseases .</segment>
<segment id="7" parent="1009" relname="span">Adult T-cell leukemia/lymphoma</segment>
<segment id="8" parent="7" relname="restatement">( ATLL )</segment>
<segment id="9" parent="1008" relname="same_unit">develops in up to 5 % of infected people ,</segment>
<segment id="10" parent="1011" relname="span">and sometimes a chronic neurodegenerative inflammatory disease</segment>
<segment id="11" parent="1012" relname="span">called HTLV-1-associated myelopathy</segment>
<segment id="12" parent="11" relname="restatement">( HAM )</segment>
<segment id="13" parent="1010" relname="same_unit">develops .</segment>
<segment id="14" parent="15" relname="concession">Although a high percentage of people remain asymptomatic during their lifetime ,</segment>
<segment id="15" parent="1014" relname="span">a great number of infected people develop a large range of neurological diseases .</segment>
<segment id="16" parent="1017" relname="span">Other opportunistic-like infections , such as Strongyloidiasis , Norwegian scabies , infective dermatitis , as well as autoimmune syndromes ,</segment>
<segment id="17" parent="16" relname="elaboration">including rheumatoid arthritis and Sjögren ’s syndrome ,</segment>
<segment id="18" parent="1016" relname="same_unit">have also been described among HTLV-1 carriers .</segment>
<segment id="19" parent="1019" relname="span">In these patients , the clinical conditions appear to be the result of the interaction between the virus and the host susceptibility ,</segment>
<segment id="20" parent="19" relname="elaboration">leading to the abnormal functioning of immuno-modulatory mechanisms , cell proliferation , and inflammation .</segment>
<segment id="21" parent="1021" relname="span">HAM is a chronic progressive demyelinating disease</segment>
<segment id="22" parent="1022" relname="span">that affects the spinal cord and the white matter of the brain ,</segment>
<segment id="23" parent="1023" relname="span">leading to a severe clinical syndrome</segment>
<segment id="24" parent="1024" relname="span">due to the motor limitations</segment>
<segment id="25" parent="1025" relname="span">that affect the lower limbs</segment>
<segment id="26" parent="25" relname="elaboration">associated with the autonomic dysfunction .</segment>
<segment id="27" parent="1027" relname="span">The clinical picture begins and evolves insidiously ,</segment>
<segment id="28" parent="1028" relname="span">being difficult to establish</segment>
<segment id="29" parent="28" relname="circumstance">when the first symptoms appeared .</segment>
<segment id="30" parent="1005" relname="joint">The main signs and symptoms of HAM may include gait disturbance , weakness , and stiffness of the lower limbs .</segment>
<segment id="31" parent="1005" relname="joint">The first manifestations of the disease occur in the fourth decade of life</segment>
<segment id="32" parent="1005" relname="joint">and there is a 2:1 woman/man ratio .</segment>
<segment id="33" parent="1005" relname="joint">The incubation period differs from patient to patient</segment>
<segment id="34" parent="1034" relname="span">and seems to be shorter in the cases</segment>
<segment id="35" parent="34" relname="elaboration">where the virus was acquired through blood transfusion .</segment>
<segment id="36" parent="1036" relname="span">Two important aspects of HAM development have been reported ,</segment>
<segment id="37" parent="1037" relname="span">including the efficiency of the cellular immune response and the rate of spontaneous expression of the viral antigen ,</segment>
<segment id="38" parent="1038" relname="span">due to the numerous immunological alterations ,</segment>
<segment id="39" parent="1039" relname="span">mediated mainly by the expression of Tax</segment>
<segment id="40" parent="1040" relname="span">( regulatory protein of the virus )</segment>
<segment id="41" parent="40" relname="elaboration">in the peripheral blood and in the cerebrospinal fluid of patients with HAM .</segment>
<segment id="42" parent="43" relname="purpose">In order to control HTLV-1 replication and the proliferation of infected cells ,</segment>
<segment id="43" parent="1042" relname="span">CD8+ T lymphocytes mediate the main defense strategy of the host immune system .</segment>
<segment id="44" parent="1044" relname="span">HTLV-1 infects mainly CD4+ T cells ,</segment>
<segment id="45" parent="1045" relname="span">which are the central regulators of the acquired immune response ,</segment>
<segment id="46" parent="45" relname="elaboration">deregulating the host immune system .</segment>
<segment id="47" parent="1047" relname="joint">To establish persistent infection ,</segment>
<segment id="48" parent="1048" relname="joint">HTLV-1 deregulates CD4+ T cells ,</segment>
<segment id="49" parent="1048" relname="joint">sometimes leading to ATLL or to chronic inflammatory diseases , such as HAM and uveitis .</segment>
<segment id="50" parent="1050" relname="span">The absence of symptoms in most of the infected people raises the question of the multiple etiological roles of the virus-associated diseases</segment>
<segment id="51" parent="50" relname="elaboration">and some of the interesting questions still unanswered includes :</segment>
<segment id="52" parent="1052" relname="span">does the immunogenic characteristics of the host contribute to the upsurge of symptoms</segment>
<segment id="53" parent="52" relname="elaboration">associated with HTLV-1 infection ?</segment>
<segment id="54" parent="1053" relname="span">The present manuscript presents the most relevant published results from several laboratories , including ours over the years</segment>
<segment id="55" parent="1055" relname="span">regarding the associations between the genetic variations of the host</segment>
<segment id="56" parent="55" relname="elaboration">related to the immune response and HTLV-1 infection ,</segment>
<segment id="57" parent="1056" relname="span">particularly those</segment>
<segment id="58" parent="57" relname="elaboration">showing the close relationship between HTLV-1 infection and single nucleotide polymorphisms in genes of the immune system .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1005" relname="background"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="multinuc" parent="1001" relname="span"/>
<group id="1008" type="multinuc" parent="1005" relname="joint"/>
<group id="1009" type="span" parent="1008" relname="same_unit"/>
<group id="1010" type="multinuc" parent="1005" relname="joint"/>
<group id="1011" type="span" parent="1010" relname="same_unit"/>
<group id="1012" type="span" parent="10" relname="elaboration"/>
<group id="1014" type="span" parent="1005" relname="joint"/>
<group id="1016" type="multinuc" parent="1005" relname="joint"/>
<group id="1017" type="span" parent="1016" relname="same_unit"/>
<group id="1019" type="span" parent="1005" relname="joint"/>
<group id="1021" type="span" parent="1005" relname="joint"/>
<group id="1022" type="span" parent="21" relname="elaboration"/>
<group id="1023" type="span" parent="22" relname="elaboration"/>
<group id="1024" type="span" parent="23" relname="cause"/>
<group id="1025" type="span" parent="24" relname="elaboration"/>
<group id="1027" type="span" parent="1005" relname="joint"/>
<group id="1028" type="span" parent="27" relname="elaboration"/>
<group id="1034" type="span" parent="1005" relname="joint"/>
<group id="1036" type="span" parent="1005" relname="joint"/>
<group id="1037" type="span" parent="36" relname="elaboration"/>
<group id="1038" type="span" parent="37" relname="cause"/>
<group id="1039" type="span" parent="38" relname="elaboration"/>
<group id="1040" type="span" parent="39" relname="elaboration"/>
<group id="1042" type="span" parent="1005" relname="joint"/>
<group id="1043" type="span" parent="1005" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="span" parent="44" relname="elaboration"/>
<group id="1046" type="multinuc" parent="1044" relname="purpose"/>
<group id="1047" type="multinuc" parent="1046" relname="joint"/>
<group id="1048" type="multinuc" parent="1047" relname="joint"/>
<group id="1049" type="span" parent="1046" relname="joint"/>
<group id="1050" type="span" parent="1051" relname="preparation"/>
<group id="1051" type="multinuc" parent="1049" relname="span"/>
<group id="1052" type="span" parent="1051" relname="joint"/>
<group id="1053" type="span" parent="1051" relname="joint"/>
<group id="1054" type="multinuc" parent="54" relname="elaboration"/>
<group id="1055" type="span" parent="1054" relname="same_unit"/>
<group id="1056" type="span" parent="1054" relname="same_unit"/>
	</body>
</rst>
